06/04/2026
A one-time infusion that permanently lowers your cholesterol. That's the promise behind a new gene editing therapy that just had results published in the New England Journal of Medicine.
The treatment is called VERVE-102, made by Eli Lilly. It's a single IV infusion that edits one gene in your liver called PCSK9. That gene controls how much LDL cholesterol your body keeps in your blood. Turn it off and your LDL drops.
In this trial, at the highest dose, LDL fell up to 62%. One infusion. Effects held steady over the follow-up period.
The idea behind it is interesting. Some people are born with this gene already switched off naturally. They carry very low cholesterol their entire lives and have dramatically lower rates of heart disease. This therapy is trying to give that same advantage to people who weren't born with it.
Now, the caveats. And there are real ones.
This was a very early, very small study. 35 patients. Side effects were mostly mild, but the follow-up period is short. Larger trials haven't started yet. We don't know what 5, 10, or 20 years looks like after this kind of edit.
And here's the part that deserves serious thought: this is permanent. You can stop taking a statin. You can't un-edit your genes. Permanence is the selling point, but it's also the risk. If something unexpected shows up down the road, there's no off switch.
I'm sharing this because the science is worth watching, not because I think anyone should be lining up for it. This is how medicine advances. Slowly, carefully, with a lot more data still needed. I'll keep following it.
https://www.nejm.org/doi/full/10.1056/NEJMoa2601283
This post is for educational purposes only and does not constitute medical advice. Talk to your doctor before making any decisions about testing or treatment.*